Jun
10
2021
On demand

Overcoming purification challenges in antibody therapeutics manufacturing with subdomain-specific affinity solutions

Since the first monoclonal antibody therapy was approved by the FDA in 1986, antibody engineering has dramatically evolved. Therapeutic antibodies have become the predominant class of biological drugs and are used to treat a variety of diseases including many types of cancer. With the development of novel bio-therapeutic antibody formats, such as bi-specific monoclonal antibodies, Fab fragments and Fc-fusion proteins, new purification challenges in the downstream process of these molecules arise. 

With an altered or absent Fc-region, the use of bacterial surface proteins such as Protein A or L, is not always the most efficient solution for the purification of these novel modalities. Affinity chromatography resins, specifically developed to bind antibody subdomain regions, can provide an alternative solution in the purification process of a variety of antibody formats, thereby allowing commercial production of antibody therapeutics.

Attendees will learn:

  • Learn more on antibody subdomain-specific affinity chromatography and how it can benefit the overall productivity of your purification workflow.
  • Get real examples showcasing the use of these resins in the development of novel antibody therapeutics.

Laurens Sierkstra

Senior Director, Business Leader, Purification, Thermo Fisher Scientific

Laurens received his PhD in biotechnology in 1994 from the University of Utrecht after studying biology at the University of Leiden. He then joined Unilever as Project Manager and Unit Leader. In 2005, after the spinout of BAC BV from Unilever, he became CEO of BAC BV and set up the business in using single- domain antibodies for affinity purification, called CaptureSelect, which was sold in 2013 to Life Technologies.

Since the acquisition by Thermo Fisher Scientific, he has been the business leader for the affinity purification business within the Bioproduction Division.

SPEAKERS

Laurens Sierkstra
Senior Director, Business Leader, Purification, Thermo Fisher Scientific

You might also like

Thinking translational: Things to consider in CAR T cell research workflows

S Rösch, PhD
Saskia Rösch, PhD
Saskia Rösch, PhD
Global Product Manager at Miltenyi Biotec
22 Jun 2022
36
Days
8
Hrs
33
Min
Register

Monitoring of circulating CAR T cells

A Graband,
D Hünecke,
D Bremm
Annika Graband
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
Dr. Sabine Hünecke
Dr. Sabine Hünecke
Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
Dr. Melanie Bremm
Dr. Melanie Bremm
Deputy Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
31 May 2022
14
Days
8
Hrs
33
Min
Register

Improving T cell therapy manufacturing processes with automation and...

E Zynda, PhD
Evan Zynda, PhD
Evan Zynda, PhD
Staff Scientist, Cell Biology at Thermo Fisher Scientific
26 May 2022
9
Days
8
Hrs
33
Min
Register

Streamlined workflow solutions for cell and gene therapy analytics

A Graband
Annika Graband
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
24 May 2022
7
Days
8
Hrs
33
Min
Register

Strategic partnering to enable cell therapy commercialization

J Smith
X de Mollerat du Jeu
Jenessa Smith
Jenessa Smith
Associate Director of Process Development at ArsenalBio
Xavier de Mollerat du Jeu
Xavier de Mollerat du Jeu
Senior Director, R&D, Cell and Gene Therapy at Thermo Fisher Scientific
12 May 2022
Watch now